APL
, one of the largest manufacturers of extemporaneous medicines and a leading contract development and manufacturing organization (CDMO) in Sweden, has joined forces with
CurifyLabs
, a Finnish health tech company creating personalized
medicine
manufacturing solutions, to improve the administration of medicines to children and
critically
ill
patients
using novel
3D
printing
technology
.
Compared with traditional pharmaceutical processes,
3D
printing
can produce more personalized dosages and dosage forms, with flexible shapes and structures. It also enables precise dosing, which helps reduce side effects.
APL
uses a manufacturing method that produces at least 100 capsules per batch, but with
3D
printing
technology
, precise doses can be created, reducing waste and promoting sustainability. This automated approach will also provide a better working environment for staff, with a lower risk of repetitive strain injuries and limited exposure to toxic substances.
Erik Haeffler, Chief Executive Officer at
APL
, said, “We are very impressed with
CurifyLabs
’ commitment to supporting us on our journey to address the urgent unmet needs of
critically
ill
patients
.
3D
printing
is an exciting
technology
that is well-suited to extemporaneous manufacturing. It will give us additional opportunities to fulfill our public policy assignment.”
“
APL
has demonstrated its strong capabilities in extemporaneous medicines with high quality and consistency, which will be critical to accelerating our development efforts together. We look forward to combining our strengths to create even greater value for
patients
needing personalized medicines,” added Charlotta Topelius, Chief Executive Officer at
CurifyLabs
.
APL
expects to provide fully compliant and validated
3D
-printed extemporaneous medicines to the Swedish market by 2025, with the first
3D
printers to be delivered in September 2024.
content
See Full Bio
